Opendata, web and dolomites

RESPINE SIGNED

REgenerative therapy of intervertebral disc: a double blind phase 2b trial of intradiscal injection of mesenchymal stromal cells in degenerative disc disease of the lomber SPINE unresponsive to conventional therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESPINE project word cloud

Explore the words cloud of the RESPINE project. It provides you a very rough idea of what is the project "RESPINE" about.

24    back    innovative    allogeneic    trial    marketed    chronic    disabling    transfer    78    organisation    disease    efficacy    progressive    therapies    immune    below    stem    allogenic    mesenchymal    applicable    first    health    clinic    112    functional    indexes    clinical    diseases    pain    demonstrated    bm    adjacent    clinically    msc    unmet    list    multicentre    sustainably    world    strategy    surgery    2b    intervertebral    rigorously    segments    procedure    standardised    degeneration    randomized    cells    10k    cell    months    twelve    biomechanical    trials    treatment    disability    rapid    encouraging    thanks    prepared    relaxation    smes    function    exhibited    invasive    improvement    automation    accelerated    safety    intradiscal    50    least    2a    mechanical    disc    notably    degenerative    65    receive    injection    patients    therapy    proven    efficient    mri    respine    ddd    reduce    broadly    standardisation    regenerative    minimally    t2    medical   

Project "RESPINE" data sheet

The following table provides information about the project.

Coordinator
CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER 

Organization address
address: AVENUE DU DOYEN GASTON GIRAUD 191
city: MONTPELLIER
postcode: 34000
website: www.chu-montpellier.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.chu-montpellier.fr/
 Total cost 5˙555˙836 €
 EC max contribution 5˙555˙836 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER FR (MONTPELLIER) coordinator 837˙963.00
2    CITOSPIN S.L. ES (VALLADOLID) participant 964˙126.00
3    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 495˙750.00
4    UNIVERSIDAD DE VALLADOLID ES (VALLADOLID) participant 402˙537.00
5    CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES FR (NANTES) participant 375˙125.00
6    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) participant 363˙000.00
7    UNIVERSITA CAMPUS BIO MEDICO DI ROMA IT (ROMA) participant 321˙362.00
8    INSTITUT DE TERAPIA REGENERATIVA TISULAR SL ES (BARCELONA) participant 300˙860.00
9    BG KLINIKUM BERGMANNSTROST HALLE GGMBH DE (HALLE) participant 260˙012.00
10    NATIONAL UNIVERSITY OF IRELAND GALWAY IE (Galway) participant 258˙745.00
11    UNIVERSITE DE MONTPELLIER FR (MONTPELLIER) participant 249˙500.00
12    UNIVERCELL BIOSOLUTIONS SAS FR (TOULOUSE) participant 233˙716.00
13    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 220˙306.00
14    ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK FR (PARIS) participant 177˙150.00
15    CENTRE HOSPITALIER UNIVERSITAIRE DE RENNES FR (RENNES CEDEX 9) participant 95˙679.00

Map

 Project objective

The World Health Organisation (WHO) has included low back pain in its list of twelve priority diseases. Notably, Degenerative disc disease (DDD) presents a large, unmet medical need which results in a disabling loss of mechanical function. Today, no efficient therapy is available. Chronic cases often receive surgery, which may lead to biomechanical problems and accelerated degeneration of adjacent segments. Our consortium partners have developed and studied stem cell-based, regenerative therapies with encouraging results in phase 1 and 2a trials. Patients exhibited rapid and progressive improvement of functional and pain indexes by 50% within 6 months and by 65% to 78% after 1 year with no side effects. In addition, MRI T2 relaxation measurements demonstrated a significant improvement. To develop the world’s first rigorously proven, effective treatment of DDD, RESPINE aims to assess, via a multicentre, randomized, controlled, phase 2b clinical trial including 112 patients with DDD, the efficacy of an allogenic intervertebral mesenchymal stem cell (MSC)-based therapy. This innovative therapy aims to rapidly (within 3 months) and sustainably (at least 24 months) reduce pain and disability. In addition, the consortium aims to provide new knowledge on immune response & safety associated with allogeneic BM-MSC intradiscal injection. This simple procedure would be cost-effective, minimally invasive, and standardised. The transfer to the clinic will be prepared at a cost below 10k€ thanks to the strategy of production of allogenic cells, automation & EU standardisation. At the end of the RESPINE trial, we aim to propose a broadly available and clinically applicable treatment for DDD, marketed by European SMEs.

 Deliverables

List of deliverables.
Dissemination and Communication Documents, reports 2020-03-23 11:32:02
Registration of clinical trial on EudraCT and Clinicaltrials.gov Documents, reports 2020-03-23 11:32:02

Take a look to the deliverables list in detail:  detailed list of RESPINE deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Abbie. L. A. Binch, Stephen M. Richardson, Judith A. Hoyland, Frank P. Barry
Combinatorial conditioning of adipose derived‐mesenchymal stem cells enhances their neurovascular potential: Implications for intervertebral disc degeneration
published pages: , ISSN: 2572-1143, DOI: 10.1002/jsp2.1072
JOR SPINE 2/4 2020-03-23

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESPINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESPINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More